参考文献/References:
[1] Koupenova M,Clancy L,Corkrey HA,et al. Circulating platelets as mediators of immunity,inflammation,and thrombosis[J]. Circ Res,2018,122(2):337-351.
[2] Wendelboe AM,Raskob GE. Global burden of thrombosis:epidemiologic aspects[J]. Circ Res,2016,118(9):1340-1347.
[3] Lanza GM,Cui G,Schmieder AH,et al. An unmet clinical need:the history of thrombus imaging[J]. J Nucl Cardiol,2019,26(3):986-997.
[4] Hafiane A. Vulnerable plaque,characteristics,detection,and potential therapies[J]. J Cardiovasc Dev Dis,2019,6(3):26.
[5] van der Meijden PEJ,Heemskerk JWM. Platelet biology and functions:new concepts and clinical perspectives[J]. Nat Rev Cardiol,2019,16(3):166-179.
[6] Yeung J,Li W,Holinstat M. Platelet signaling and disease:targeted therapy for thrombosis and other related diseases[J]. Pharmacol Rev,2018,70(3):526-548.
[7] Lindner JR,Song J,Christiansen J,et al. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin[J]. Circulation,2001,104(17):2107-2112.
[8] Davidson BP,Chadderdon SM,Belcik JT,et al. Ischemic memory imaging in nonhuman primates with echocardiographic molecular imaging of selectin expression[J]. J Am Soc Echocardiogr,2014,27(7):786-793.
[9] Appeldoorn CC,Molenaar TJ,Bonnefoy A,et al. Rational optimization of a short human P-selectin-binding peptide leads to nanomolar affinity antagonists[J]. J Biol Chem,2003,278(12):10201-10207.
[10] Xu J,Zhou J,Zhong Y,et al. Phase transition nanoparticles as multimodality contrast agents for the detection of thrombi and for targeting thrombolysis:in vitro and in vivo experiments[J]. ACS Appl Mater Interfaces,2017,9(49):42525-42535.
[11] Rouzet F,Bachelet Violette L,Alsac JM,et al. Radiolabeled fucoidan as a p-selectin targeting agent for in vivo imaging of platelet-rich thrombus and endothelial activation[J]. J Nucl Med,2011,52(9):1433-1440.
[12] Suzuki M,Bachelet-Violette L,Rouzet F,et al. Ultrasmall superparamagnetic iron oxide nanoparticles coated with fucoidan for molecular MRI of intraluminal thrombus[J]. Nanomedicine(Lond),2015,10(1):73-87.
[13] Li B,Aid-Launais R,Labour MN,et al. Functionalized polymer microbubbles as new molecular ultrasound contrast agent to target P-selectin in thrombus[J]. Biomaterials,2019,194:139-150.
[14] Nguyen H,Tinet E,Chauveau T,et al. Bimodal fucoidan-coated zinc oxide/iron oxide-based nanoparticles for the imaging of atherothrombosis[J]. Molecules,2019,24(5):962.
[15] Zheng K,Kaiser Y,Poel E,et al. 99Mtc-fucoidan as diagnostic agent for P-selectin imaging:first-in-human evaluation (phase I)[J]. Atherosclerosis,2019,287:e143.
[16] Unger E,Porter T,Lindner J,et al. Cardiovascular drug delivery with ultrasound and microbubbles[J]. Adv Drug Deliv Rev,2014,72:110-126.
[17] Hu G,Liu C,Liao Y,et al. Ultrasound molecular imaging of arterial thrombi with novel microbubbles modified by cyclic RGD in vitro and in vivo[J]. Thromb Haemost,2012,107(1):172-183.
[18] Ye S,Liu Y,Lu Y,et al. Cyclic RGD functionalized liposomes targeted to activated platelets for thrombosis dual-mode magnetic resonance imaging[J]. J Mater Chem B,2020,8(3):447-453.
[19] Rix A,Fokong S,Heringer S,et al. Molecular ultrasound imaging of αvβ3- integrin expression in carotid arteries of pigs after vessel injury[J]. Invest Radiol,2016,51(12):767-775.
[20] Kang CM,Koo HJ,An GI,et al. Hybrid PET/optical imaging of integrin αVβ3 receptor expression using a (64)Cu-labeled streptavidin/biotin-based dimeric RGD peptide[J]. EJNMMI Res,2015,5(1):60.
[21] Wu Y,Wang C,Guo J,et al. An RGD modified water-soluble fluorophore probe for in vivo NIR-Ⅱ imaging of thrombosis[J]. Biomater Sci,2020,8(16):4438-4446.
[22] Bai S,Liao J,Zhang B,et al. Multimodal and multifunctional nanoparticles with platelet targeting ability and phase transition efficiency for the molecular imaging and thrombolysis of coronary microthrombi[J]. Biomater Sci,2020,8(18):5047-5060.
[23] Lim B,Yao Y,Huang AL,et al. A unique recombinant fluoroprobe targeting activated platelets allows in vivo detection of arterial thrombosis and pulmonary embolism using a novel three-dimensional fluorescence emission computed tomography(FLECT) technology[J]. Theranostics,2017,7(5):1047-1061.
[24] Ta H,Li Z,Hagemeyer C,et al. Self-confirming molecular imaging of activated platelets via iron oxide nanoparticles displaying unique dual MRI contrast[J]. Atherosclerosis,2017,263:e146.
[25] Ta HT,Li Z,Hagemeyer CE,et al. Molecular imaging of activated platelets via antibody-targeted ultra-small iron oxide nanoparticles displaying unique dual MRI contrast[J]. Biomaterials,2017,134:31-42.
[26] Li Y,Xin F,Hu J,et al. Functionalization of NaGdF4 nanoparticles with a dibromomaleimide-terminated polymer for MR/optical imaging of thrombosis[J]. Polym Chem,2020,11(5):1010-1017.
[27] Lin H,Xu L,Yu S,et al. Therapeutics targeting the fibrinolytic system[J]. Exp Mol Med,2020,52(3):367-379.
[28] Botnar RM,Perez AS,Witte S,et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent[J]. Circulation,2004,109(16):2023-2029.
[29] Overoye-Chan K,Koerner S,Looby RJ,et al. EP-2104R:a fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus[J]. J Am Chem Soc,2008,130(18):6025-6039.
[30] Ay I,Blasi F,Rietz TA,et al. In vivo molecular imaging of thrombosis and thrombolysis using a fibrin-binding positron emission tomographic probe[J]. Circ Cardiovasc Imaging,2014,7(4):697-705.
[31] Gale EM,Atanasova IP,Blasi F,et al. A manganese alternative to gadolinium for MRI contrast[J]. J Am Chem Soc,2015,137(49):15548-15557.
[32] Oliveira BL,Blasi F,Rietz TA,et al. Multimodal molecular imaging reveals high target uptake and specificity of 111In- and 68Ga-labeled fibrin-binding probes for thrombus detection in rats[J]. J Nucl Med,2015,56(10):1587-1592.
[33] Hara T,Bhayana B,Thompson B,et al. Molecular imaging of fibrin deposition in deep vein thrombosis using fibrin-targeted near-infrared fluorescence[J]. JACC Cardiovasc Imaging,2012,5(6):607-615.
[34] Lux J,Vezeridis AM,Hoyt K,et al. Thrombin-activatable microbubbles as potential ultrasound contrast agents for the detection of acute thrombosis[J]. ACS Appl Mater Interfaces,2017,9(43):37587-37596.
[35] Kwon SP,Jeon S,Lee SH,et al. Thrombin-activatable fluorescent peptide incorporated gold nanoparticles for dual optical/computed tomography thrombus imaging[J]. Biomaterials,2018,150:125-136.
[36] Wang Y,Xu M,Yang N,et al. A thrombin-responsive nanoprobe for in vivo visualization of thrombus formation through three-dimensional optical/computed tomography hybrid imaging[J]. ACS Appl Mater Interfaces,2021,13(24):27814-27824.
[37] Zhang Y,Zhong Y,Ye M,et al. Polydopamine-modified dual-ligand nanoparticles as highly effective and targeted magnetic resonance/photoacoustic dual-modality thrombus imaging agents[J]. Int J Nanomedicine,2019,14: 7155-7171.
[38] Günther F,Heidt T,Kramer M,et al. Dual targeting improves capture of ultrasound microbubbles towards activated platelets but yields no additional benefit for imaging of arterial thrombosis[J]. Sci Rep,2017,7(1):14898.
[39] Yang A,Qiao B,Strohm EM,et al. Thrombin-responsive engineered nanoexcavator with full-thickness infiltration capability for pharmaceutical-free deep venous thrombosis theranostics[J]. Biomater Sci,2020,8(16):4545-4558.
[40] Su M,Dai Q,Chen C,et al. Nano-medicine for thrombosis:a precise diagnosis and treatment strategy[J]. Nanomicro Lett,2020,12(1):96.